News and analysis on disease research and diagnostics.
The firm aims to offer a clinical service next year for predicting immunotherapy response and adverse immune reactions.
In a training subset of the larger cohort, the company was able to develop classifiers that detected many cancers while minimizing false positives.
Pivoting from a technology that it deemed wasn't robust enough, Confer Health is now designing a platform to enable broad-scale testing at home.
The platform, which was first developed to transmit flu data to the CDC, is expanding to multiple use cases and multiple users.
The firm hopes the effort, recently described in the journal Oncotarget, will spur adoption of its testing services by oncologists, particularly in Europe, where it is determined to become a market leader.
